author-photo

Chris Wells

Hoffmann-La Roche

15

Papers

30

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.

2021 Rheumatology
Show All
- Source
- Cite
- Save
Citations (1)
170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis

2019 Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

2019 Pediatric Rheumatology
Show All
- Source
- Cite
- Save
Citations (9)
THU0598 Safety of tocilizumab in patients aged <2 years with active systemic juvenile idiopathic arthritis treated for one year

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
OP0197 Evaluation of a dosing regimen for tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis

2017 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (2)
THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial

2015 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006)

2012 Neurology
Show All
- Source
- Cite
- Save
Citations (5)